Genome editing with #CRISPR is the most important life science breakthrough of our time. It's a B.C. and A.C. We interviewed @WalterIsaacson about his new book, THE CODE BREAKER, which is a masterpiece medscape.com/viewarticle/95…
w/ transcript /1
We started the conversation reading 2 key passages that convey the significance of #CRISPR /2
And this one /3
The book is not just about @doudna_lab and other protagonists, such as @zhangf@geochurch@EricLander46, Emmanuelle Charpentier, but thru the perspective of grad students and post docs and about team science /4
There is substantial emphasis on the power of basic science, curiosity and creativity, and not just the linear model of discovery.
"They were doing it purely out of curiosity, like Leonardo da Vinci" /5
The links to the computer, digital, coding parallel advances are striking. Everything from the Homebrew Computer Club, the Asilomar conferences (there has been one for #AI), patent fights over chips, 0|1 vs ACGT, and so much more /6
Isaacson does a wonderful job differentiating germline editing, such as the reckless #CRISPR Babies work by Jiankui, to the remarkable progress in somatic editing @davidrliu@skathire /7
For me, the most heartwarming part of the book was he how brought Doudna and Charpentier back together again.
The infamous @Zoom get together /8
I asked Walter about the importance of scientists playing a role in public policy, since that certainly was not Jennifer Doudna's background. His response is remarkably insightful (not shown here) /9
On the democratization of #CRISPR, Isaacson takes a bit of a contrarian view (from the life science community) in supporting the DIY work of @4LOVofScience /10
Both @cuttingforstone and I were so deeply impressed with how lucid he made such a complex topic & into a veritable page turner. I can't recommend it enough fo anyone wanting to learn more about this breakthrough— it will have transformative impact in medicine and science
• • •
Missing some Tweet in this thread? You can try to
force a refresh
New US Covid genomic surveillance
The KP.3.1.1 variant is on the move to become dominant, more of a challenge to our immune response than KP.3 and prior variants (especially without new KP.2 booster when we need it for high-risk individuals)
It's the deletion 31/31 that makes the KP.3.1.1 spike different, but otherwise 2 mutations away from KP.2 (R346T and Q493E)
Buckle up; this wave isn't over yet d/t KP.3.1.1's emergence
We've known about KP.3's marked growth advantage since April and could have made the call then to make the new booster. That would have been aligned well with the current wave (available in July) 2/5 erictopol.substack.com/p/are-we-flirt…
But the FDA has tried to force fit Covid into an annual shot like flu, even though all data tells us it doesn't follow an annual pattern. Even the CDC acknowledges this now
3/5cdc.gov/ncird/whats-ne…
New CDC genomic data shows continued rise of the KP.3 variant that accounts for 1 of 3 Covid cases.
LB.1 is gaining, too, as JN.1 fades away
This variant growth advantage plot by @BenjMurrell (H/T @siamosolocani) shows why this is the case. Note KP.3 is the one at far left w/ almost 3-fold advantage to JN.1.
Reinforces why the decision to develop the KP.2 vaccine booster (instead of JN.1) was a good one
Spike mutation map to show the differences betweem KP.3 and JN.1 (and LB.1, KP.2)
The connection between #SARSCoV2 and neurodegeneration
@TheLancetNeuro
Quotes below: 1. SARS-CoV-2 infection should be considered as a risk factor for Alzheimer’s disease, even though the distinction between causation versus disease acceleration is not clear.thelancet.com/journals/laneu…
2. Inflammation in patients with COVID-19, and controlled experiments show prolonged neuro-inflammation after mild SARS-CoV-2 infection
in macaques.
3. A direct correlation has been reported
between prior SARS-CoV-2 infection and increased risk
of Alzheimer’s disease (figure).
4. So far, the estimated lifetime cumulative risk of dementia due to hospitalisation for any viral infection is 1·48 (95% CI 1·15–1·91).
Breaking down the risks and benefit for lecanemab, the amyloid beta-directed antibody vs Alzheimer's drug approved @US_FDA last year. It doesn't look good.